While ozmpic Dominated weight loss spaceVegovi and Mounaro Other injection prescriptions are worth knowing about the weight loss drugs. But can these weight loss injections actually help people to lose weight and keep it off? What about health risks and side effects? While these drugs can serve a very important purpose for some people, they also come with some risks.Also read 7 Weight Los myths were busting by celebrity fitness trainer Tridev Pandey: ‘Never go for ozmpic …’
In an interview with HT lifestyle, Endocrinologist, Dr. Saptrishshi Bhattacharya, Senior Advisor, Indraprastha Apollo Hospitals, Delhi and Secretary, Endocrine Society of Delhi, said that for some people, these, these, these, these Upheaval injectionAs a groundbreaking solutions, it looks like a beacon of hope.
“Still his popularity increases, a shadow of controversy.
Dr. According to Bhattacharya, while manufacturing companies said that they have not done anything wrong, the investigation is increasing, all have been urged to re -prepare the safety of these treatments: “Against this background, it becomes important to turn towards medical evidence rather than headlines.”
Are Anti-Motapa injections really effective?
Dr. Bhattacharya said, “Medical literature clearly reflects the efficacy of anti-obesity injection, such as semglutide (vegovi and ozmpic) and tirzepetide (Maunjaro), marking a new era. weight managementClinical trials have displayed that these drugs can lead to sufficient and continuous weight loss. ,
He said in detail: “For example, the study on Semaglutide has reported an average weight loss of 17 percent in 68 weeks, in which one-third of the participants have shed 20 percent of their body weight. To keep it in perspective, a person weighing 100 kg can expect to lose 17 kg, and in one-third of cases, more than 20 kg.”
He said, “Tirzepetide has shown comparable, and in some cases, even more efficacy in weight loss. On average, the participants lost about 15-20 percent of their body weight, once possible was possible only once the scale of deficiency was possible only after the bariatric surgery. Remarkable, more than 60 percent of the dose was lost at a dose of about 60 percent, the dose of more than 60 percent was lost, the dose was lost.
Dr. According to Bhattacharya, these drugs bring heart and metabolic benefits beyond the pretext of only the kilo. “They improve blood sugar, blood pressure, and lipid profiles and reduce systemic inflammation. In particular, semaglutide reduces the risk of major adverse cardiovascular phenomena in individuals with heart disease. Research also indicates improvement in obesity related conditions, such as obstructive sleep aponasia and metabolic dysfunction-state-related liver, general Known, fatty liverBy advancing the extensive health benefits of these drugs. ,
So where is hesitation?
While anti-observance jabs promise dramatic results, they do not come without side-effects. Dr. Bhattacharya shared that the most common problems include intestines, such as nausea, diarrhea, constipation, abdominal pain and sometimes vomiting. They said that nausea At the top of the list, affects up to 44 percent of people, who take semaglutide and about 30 percent people take tirzepetides.
“Diarrhea also occurs often, 20–30 percent is seen in users, while vomiting affects about 10–15 percent and constipation 10–20 percent. For most, these symptoms are mild to moderate in intensity, in the early weeks of therapy or after changes in a dose, at least for vomiting and direct.
He said that these intestinal problems are estimated and in fact, arise from the same hunger-dominated action that makes drugs effective. But real concern, Dr. According to Bhattacharya, this is: Can there be just risks beyond nausea and diarrhea? “Reports have expressed concern about rare but serious complications like pancreatitis, Intestinal obstruction Gastropariasis and paralytic Iiyas are called, and a vision problem known as non-artetic anterior ischemic optic neuropathy (Naion), which can cause sudden vision loss. Although these serious events are rare, their possibility means that drugs still need careful monitoring, even they help many people to lose weight effectively, ”he said.
Do these drugs increase the risk of pancreatitis?
Dr. Bhattacharya said that large -scale clinical trials assured, showing that the risk of pancreatitis (swelling of the pancreas) with these drugs is very low, often not more than a placebo (dummy drug): “For example, a large test of semglutide reported a 0.5 percent compared to only 0.5 percent. Reported a 0.5 percent compared to a 0.5 percent. Drug and plasbow groups in the drug and plasbow groups. With a study to detect.
He said, “With persons Type 2 diabetes And obesity already has a high infrastructure risk for pancreatitis, and without indicating a real illness, these conditions are slightly elevated pancreatic enzymes (lips and amylase). Nevertheless, users (of these drugs) should be cautious to symptoms of severe abdominal pain, especially if radiation on the back, and if this happens, attract immediate medical attention. Doctors use these injections with extreme caution, or even avoid them, in people with pre -pancreatitis history or in high risk people. ,
What is paralyzed or gastrointestinal Iiyas?
Dr. According to Bhattacharya, a rare anxiety is paralyzed Ilyas, where the intestines stop moving properly. He said that the US Federal Drug Monitoring Body, FDA has issued a warning about the gastrointestinal Ilyas on the label for semaglutide.
“This alert comes after a post-marketing report from users. While the exact cause is still under investigation, semglutide and tirzepetide are known to empty gastric and change intestinal dynamics. A detailed investigation, however, it was found that the semglutide itself was found to Individual cases of small bowel obstruction have been noted. Gas or stool Ilies may indicate and require immediate medical treatment, ”shared by Dr. Bhattacharya.
Concern about naion
A vision-related anxiety that has come to mind is non-ethic anterior ischemic optic neuropathy. Dr. Bhattacharya shared the European Medicine Agency (EMA), recently concluded that the Naian is a very rare side effect of semaglutide, which is estimated to affect 1 in 10,000 users.
“A large American study of more than 159,000 participants with Type 2 diabetes found that during two years of follow -up, Naion took place in 0.04 percent, which does not prove to be a matching comparison in comparison group compared to 0.02 percent of the people taking semaglutide or tirzepetide, and big studies have already made a clear change, but no one has a clear change, but no one has a clear change on these drugs, but no one has already changed, but no longer change the drugs. Should not be ignored, ”he said.
Where are we standing now?
“A 2024 survey found that about 6 percent of American adults, or about 6 million people, a GLP-1 agonist, such as Semglutide, who were taking the most widely used anti-anti-anti-anti-anti-anti-drugs. Millions of people worldwide have benefited, and demand continues to increase the chains of global supply,”.
Legal concerns have come to light with this unprecedented rise. Dr. Bhattacharya shared: “By September 2025, more than 2,600 cases are pending in federal courts in Pennsylvania, USA, both Novo Nordisk, the creator of Vagovi, and the creator of Eli Lily, Maunjaro, to fail to the plaintiff, gallbladder, and a federal jurisdiction.
Legal development underlines the importance of selecting appropriate candidates and maintaining ongoing monitoring. “Medical evidence clearly shows the benefits of these drugs, including significant weight loss, Better blood sugar controlLow cardiovascular risk, better sleep apnea result, and liver and kidney health protection. The presence of rare side effects should not be separated to individuals who stand for benefit from these treatments. However, there should be clear communication about the risks and warnings associated with their use, ”said Dr. Bhattacharya.
“It is important to create a balance between caution and activation, with the long-term and often-compliance results of untreated obesity.
Note the readers: This article is only for informative purposes and is not an option for professional medical advice. Always consult your doctor with any question about a medical condition.
